Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
Objective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of mTOR (mammalian target of rapamycin), and clinical trials for tuberous sclerosis complex (TSC), neurofibromatosis-1 (NF1) and fragile X syndrome (FXS), and phosphatas...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Neural Plasticity |
| Online Access: | http://dx.doi.org/10.1155/2012/486402 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850234765436780544 |
|---|---|
| author | Tanjala T. Gipson Michael V. Johnston |
| author_facet | Tanjala T. Gipson Michael V. Johnston |
| author_sort | Tanjala T. Gipson |
| collection | DOAJ |
| description | Objective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of mTOR (mammalian target of rapamycin), and clinical trials for tuberous sclerosis complex (TSC), neurofibromatosis-1 (NF1) and fragile X syndrome (FXS), and phosphatase and tensin homolog hamartoma syndromes (PTHS), which are neurogenetic disorders associated with abnormalities in synaptic plasticity and mTOR signaling. Methods. Pubmed and Clinicaltrials.gov were searched using specific search strategies. Results/Conclusions. Although traditionally thought of as irreversible disorders, significant scientific progress has been made in both humans and preclinical models to understand how pathologic features of these neurogenetic disorders can be reduced or reversed. This paper revealed significant similarities among the conditions. Not only do they share features of impaired synaptic plasticity and dysregulation of mTOR, but they also share clinical features—autism, intellectual disability, cutaneous lesions, and tumors. Although scientific advances towards discovery of effective treatment in some disorders have outpaced others, progress in understanding the signaling pathways that connect the entire group indicates that the lesser known disorders will become treatable as well. |
| format | Article |
| id | doaj-art-0f84057816484df9b8a2c3c13ca778d2 |
| institution | OA Journals |
| issn | 2090-5904 1687-5443 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neural Plasticity |
| spelling | doaj-art-0f84057816484df9b8a2c3c13ca778d22025-08-20T02:02:32ZengWileyNeural Plasticity2090-59041687-54432012-01-01201210.1155/2012/486402486402Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic DisordersTanjala T. Gipson0Michael V. Johnston1Tuberous Sclerosis Center, Hugo Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205, USATuberous Sclerosis Center, Hugo Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205, USAObjective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of mTOR (mammalian target of rapamycin), and clinical trials for tuberous sclerosis complex (TSC), neurofibromatosis-1 (NF1) and fragile X syndrome (FXS), and phosphatase and tensin homolog hamartoma syndromes (PTHS), which are neurogenetic disorders associated with abnormalities in synaptic plasticity and mTOR signaling. Methods. Pubmed and Clinicaltrials.gov were searched using specific search strategies. Results/Conclusions. Although traditionally thought of as irreversible disorders, significant scientific progress has been made in both humans and preclinical models to understand how pathologic features of these neurogenetic disorders can be reduced or reversed. This paper revealed significant similarities among the conditions. Not only do they share features of impaired synaptic plasticity and dysregulation of mTOR, but they also share clinical features—autism, intellectual disability, cutaneous lesions, and tumors. Although scientific advances towards discovery of effective treatment in some disorders have outpaced others, progress in understanding the signaling pathways that connect the entire group indicates that the lesser known disorders will become treatable as well.http://dx.doi.org/10.1155/2012/486402 |
| spellingShingle | Tanjala T. Gipson Michael V. Johnston Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders Neural Plasticity |
| title | Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders |
| title_full | Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders |
| title_fullStr | Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders |
| title_full_unstemmed | Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders |
| title_short | Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders |
| title_sort | plasticity and mtor towards restoration of impaired synaptic plasticity in mtor related neurogenetic disorders |
| url | http://dx.doi.org/10.1155/2012/486402 |
| work_keys_str_mv | AT tanjalatgipson plasticityandmtortowardsrestorationofimpairedsynapticplasticityinmtorrelatedneurogeneticdisorders AT michaelvjohnston plasticityandmtortowardsrestorationofimpairedsynapticplasticityinmtorrelatedneurogeneticdisorders |